



AP32737 072396.0225
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robbins et al.

Serial No.: 09/844,915

Examiner: Gibbs, Terra C.

Filing Date: April 27, 2001

Group Art: 1635

Title of Invention: THE USE OF TOLEROGENIC DENDRITIC CELLS FOR
ENHANCING THE TOLEROGENICITY IN A HOST AND METHODS
FOR MAKING THE SAME

RECEIVED
JUN 24 2003
TECH CENTER 1600/2900

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal
Service as first class mail in an envelope addressed to: Commissioner for
Patents, Box 1450, Alexandria, VA 22313-1450.

June 16, 2003


Date of Deposit

Alicia A. Russo

Attorney's Name

46,192

Registration No.


Signature

June 16, 2003

Date of Signature

Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicants respectfully request that the
documents listed below and on the accompanying PTO 1449 be considered by the Examiner and
made of record in the above-referenced application. Copies of the listed documents are enclosed.

06/20/2003 ZJUWAR1 00000093 024377 09844915

01 FC:1806 180.00 DA

NY02:444371.1

1. Ma et al., "Dual modifications, NF- κ B deficiency and overexpression of IL-10, enhance DC tolerogenic activity," presented at American Transplant Congress 2003, May 30-June 4, Washington, DC.

2. Bonham et al., "Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF κ B oligonucleotide decoys and adenoviral vectors encoding CTLA4-Ig¹," Journal of Immunology, 2002, 169:3382-3391.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution, and accompanied by the fee set forth in 37 C.F.R. § 1.17(p). If any additional fee is due, or if any overpayment has been made, the Commissioner is authorized to charge any such fee or credit any overpayment, to our Deposit Account No. 02-4377.

AP32737 072396.0225
PATENT

Duplicate copies of this sheet are enclosed.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Rochelle K. Seide", is written over a horizontal line.

Rochelle K. Seide
Patent Office Reg. No. 32,300


Carmella L. Stephens
Patent Office Reg. No. 41,328

Alicia A. Russo
Patent Office Reg. No. 46,192

Attorneys for Applicants
(212) 408-2500

Atty. Docket No.
A32737 072396.0225

Serial No.
09/844,915




**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

Applicant
Robbins et al.

Filing Date
April 27, 2001

Group Art Unit
1633



U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENT

Document No.	Date	Country	Class	SubClass	Translation Yes No

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

	Ma et al., "Dual modifications, NF- κ B deficiency and overexpression of IL-10, enhance DC tolerogenic activity," presented at American Transplant Congress 2003, May 30-June 4, Washington, DC.
	Bonham et al., "Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF κ B oligonucleotide decoys and adenoviral vectors encoding CTLA4-Ig ¹ ," Journal of Immunology, 2002, 169:3382-3391.

NY02:444373.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.